Debiopharm Research & Manufacturing SA, a global biopharmaceutical company based in Switzerland dedicated to curing cancer and infectious diseases, and Oncodesign Services, a leading contract research organization (CRO) specializing in drug discovery and preclinical services, announce the signing of a license agreement for the use of AbYlink™ technology for preclinical services.
AbYlink™ is a regioselective bioconjugation technology ideal for the production of conjugates for therapeutic and non-invasive diagnostic applications. Oncodesign Services will utilize this cutting-edge technology to produce antibody-chelator conjugates for preclinical studies to gain insights into the predictive efficacy of novel treatment approaches in molecular radiotherapy, and particularly radioimmunotherapy, in cancer. A joint poster demonstrating the use of the non-invasive technology in radioimmunotherapy of HER2+ tumors in animal models will be presented at the 2025 AACR Annual Meeting.
Also Read: Orsini Launches ORBIT Track™ to Boost Biopharma Solutions
“We have demonstrated the efficacy of this powerful technology for the rapid and covalent conjugation of any commercially available antibody with an imaging agent in a single step. Our strategic collaboration with Oncodesign Services enables broader access to and use of non-invasive imaging applications and offers biotech and pharmaceutical partners an innovative solution for integrating imaging into the development of new antibody- and ADC-based therapeutics,” commented Frédéric Lévy, Chief Scientific Officer at Debiopharm.
Aidan Synnott, CEO of Oncodesign Services, said: “We are delighted to add this cutting-edge technology to our portfolio for our customers. AbYlink™ technology offers the advantage of producing reproducible batches of bioconjugated antibodies and ADCs, ensuring the specificity and efficacy of targeted radiotherapy.”
Source: Businesswire